CARDIOME ANNOUNCES COMMERCIALIZATION PARTNERSHIP FOR BRINAVESS™ IN SELECT EUROPEAN MARKETS
Vancouver, Canada, July 3, 2013
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced an agreement with AOP Orphan Pharmaceuticals AG, headquartered in Vienna, Austria, to commercialize BRINAVESS™ (vernakalant intravenous) in select European markets. AOP Orphan will support Cardiome in obtaining product registrations required for the marketing and sale of BRINAVESS in the AOP Orphan countries and will actively call on customers to promote the product. Under terms of the agreement, AOP Orphan has agreed to specific annual commercial goals for BRINAVESS. Financial details of the agreement were not disclosed.
“Execution of the BRINAVESS commercial agreement with AOP Orphan fulfills a key objective in Cardiome’s European commercialization strategy,” said William Hunter, M.D., CEO of Cardiome. “Through the agreement, additional physicians and patients beyond the reach of our current sales force will have access to BRINAVESS. We are very pleased to have partnered with such a well-known, highly experienced and respected company.”
“We are excited to partner and work with Cardiome, and to add BRINAVESS to our cardiovascular drug portfolio,” said Rudolf Widmann, Ph. D., CEO of AOP Orphan. “The synergies that exist between BRINAVESS and our cardiovascular franchise should enable us to build on our existing customer base by offering a complementary product and develop new customer relationships which are key to our future growth.”
The initial term of this commercial agreement begins July 1, 2013 for the duration of three years and is renewable on an annual basis, or longer, thereafter. The AOP Orphan countries include: Austria; Bosnia and Herzegovina; Bulgaria; Croatia; Czech Republic; Estonia; Hungary; Kazakhstan; Latvia; Lithuania; Montenegro; Macedonia; Poland; Romania; Serbia; Slovakia; Slovenia; Switzerland; and Ukraine.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients around the world. Cardiome has one marketed product, BRINAVESS™ (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Forward- looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2013 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada, Europe, and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to expand commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this presentation to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; intellectual property matters, including the unenforceability or loss of patent protection resulting from third-party challenges to our patents; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; and any other factors described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
For Further Information:
Cardiome Investor Relations
(604) 676-6993 or Toll Free: 1-800-330-9928